Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway
Authors:
- 19 February 2025
- journal article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 39 (3) , 108975
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathyHuman Cell, 2024
- Preserved Lower Limb Muscle Mass Prevents Insulin Resistance Development in Nondiabetic Older AdultsJournal of the American Medical Directors Association, 2022
- Myokine, a key cytokine for physical exercise to alleviate sarcopenic obesityMolecular Biology Reports, 2022
- Adipose–Muscle crosstalk in age-related metabolic disorders: The emerging roles of adipo-myokinesAgeing Research Reviews, 2022
- Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibitionCell Metabolism, 2021
- Hippo pathway effectors YAP and TAZ and their association with skeletal muscle ageingJournal of Physiology and Biochemistry, 2021
- Puerarin ameliorates skeletal muscle wasting and fiber type transformation in STZ-induced type 1 diabetic ratsBiomedicine & Pharmacotherapy, 2021
- Cellular senescence: at the nexus between ageing and diabetesDiabetologia, 2019
- Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophyJournal of Cachexia, Sarcopenia and Muscle, 2019
- Differential association between sarcopenia and metabolic phenotype in Korean young and older adults with and without obesityObesity, 2016